These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3479807)

  • 1. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.
    Arthur LO; Pyle SW; Nara PL; Bess JW; Gonda MA; Kelliher JC; Gilden RV; Robey WG; Bolognesi DP; Gallo RC
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8583-7. PubMed ID: 3479807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    Arthur LO; Bess JW; Waters DJ; Pyle SW; Kelliher JC; Nara PL; Krohn K; Robey WG; Langlois AJ; Gallo RC
    J Virol; 1989 Dec; 63(12):5046-53. PubMed ID: 2555541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
    Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
    J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.
    Berman PW; Groopman JE; Gregory T; Clapham PR; Weiss RA; Ferriani R; Riddle L; Shimasaki C; Lucas C; Lasky LA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5200-4. PubMed ID: 2455898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.
    Robey WG; Arthur LO; Matthews TJ; Langlois A; Copeland TD; Lerche NW; Oroszlan S; Bolognesi DP; Gilden RV; Fischinger PJ
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):7023-7. PubMed ID: 3018753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
    Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.
    Nara PL; Robey WG; Pyle SW; Hatch WC; Dunlop NM; Bess JW; Kelliher JC; Arthur LO; Fischinger PJ
    J Virol; 1988 Aug; 62(8):2622-8. PubMed ID: 3392769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.
    Hu SL; Fultz PN; McClure HM; Eichberg JW; Thomas EK; Zarling J; Singhal MC; Kosowski SG; Swenson RB; Anderson DC
    Nature; 1987 Aug 20-26; 328(6132):721-3. PubMed ID: 3475581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.
    Krohn K; Robey WG; Putney S; Arthur L; Nara P; Fischinger P; Gallo RC; Wong-Staal F; Ranki A
    Proc Natl Acad Sci U S A; 1987 Jul; 84(14):4994-8. PubMed ID: 2440037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.
    Prince AM; Horowitz B; Baker L; Shulman RW; Ralph H; Valinsky J; Cundell A; Brotman B; Boehle W; Rey F
    Proc Natl Acad Sci U S A; 1988 Sep; 85(18):6944-8. PubMed ID: 3413127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9709-13. PubMed ID: 2432599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
    Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell responses to human immunodeficiency virus (HIV) and its recombinant antigens in HIV-infected chimpanzees.
    Eichberg JW; Zarling JM; Alter HJ; Levy JA; Berman PW; Gregory T; Lasky LA; McClure J; Cobb KE; Moran PA
    J Virol; 1987 Dec; 61(12):3804-8. PubMed ID: 3500328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.
    Matthews TJ; Langlois AJ; Robey WG; Chang NT; Gallo RC; Fischinger PJ; Bolognesi DP
    Haematol Blood Transfus; 1987; 31():414-22. PubMed ID: 2832276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal development of cross-neutralization between HTLV-III B and HTLV-III RF in experimentally infected chimpanzees.
    Goudsmit J; Thiriart C; Smit L; Bruck C; Gibbs CJ
    Vaccine; 1988 Jun; 6(3):229-32. PubMed ID: 3166553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.
    Zarling JM; Eichberg JW; Moran PA; McClure J; Sridhar P; Hu SL
    J Immunol; 1987 Aug; 139(4):988-90. PubMed ID: 3497202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.
    Pyle SW; Dubois GC; Robey WG; Bess JW; Fischinger PJ; Arthur LO
    J Virol; 1988 Jul; 62(7):2258-64. PubMed ID: 3163739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.